Evidence-Based Complementary and Alternative Medicine / 2014 / Article / Tab 1

Research Article

Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial

Table 1

Baseline demographics.

CharacteristicPlacebo* ( )Low dose ( )Low dose + GE ( )High dose ( )

Age (years)54.40 (11.88)53.55 (7.90)52.95 (13.73)53.55 (11.17)
Female13 (65%)15 (75%)15 (75%)14 (70%)
Race
 Caucasian10 (50%)15 (75%)15 (75%)16 (80%)
 African American10 (50%)5 (25%)3 (15%)4 (20%)
 Asian0 (0%)0 (0%)2 (10%)0 (0%)
Weight (lbs)194.66 (46.10)185.32 (50.91)192.76 (44.56)181.79 (40.56)
BMI (kg/m2)30.09 (6.30)30.30 (8.29)31.09 (5.86)29.25 (6.02)
Blood pressure
 SBP (mmHg)130.20 (15.21)125.15 (14.35)125.40 (14.01)128.75 (19.99)
 DBP (mmHg)80.95 (8.89)78.70 (5.59)78.50 (7.32)78.95 (10.16)
 Hypertensive13 (65%)12 (60%)8 (40%)11 (55%)
Cholesterol
 LDL (mg/dL)143.80 (44.03)142.35 (29.46)140.90 (37.03)140.20 (27.41)
 HDL (mg/dL)53.25 (16.01)63.30 (18.17)56.60 (15.10)58.25 (23.41)
 Triglycerides (mg/dL)118.45 (55.02)109.95 (45.40)163.90 (70.57)124.50 (82.94)
Cholesterol medication8 (40%)7 (35%)7 (35%)7 (35%)
 Statin6 (30%)6 (30%)7 (35%)6 (30%)
Smokers0 (0%)3 (15%)2 (10%)3 (15%)
ASCVD risk score (%)6.8 (5.1)7.5 (11.6)7.5 (10.1)8.6 (7.6)
Framingham 10-year risk (%)5.70 (6.87)5.50 (7.27)6.40 (8.80)5.80 (5.88)

Values are mean (SD) or (%).
BMI: body mass index; LDL: low-density lipoprotein; HDL: high-density lipoprotein; TG: triglycerides; ASCVD: atherosclerotic cardiovascular disease.
denote that these data are “Compared to Placebo”.